Back to Search Start Over

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension

Authors :
Ayako Makino
Ankit A. Desai
Ramon J. Ayon
Yali Gu
Ziyi Wang
Qian Zhang
Guofei Zhou
Shanshan Song
Franz Rischard
Jiwang Chen
Jason X.-J. Yuan
Kang Wu
Sujana Vinjamuri
Angela Balistrieri
Haiyang Tang
Rebecca Vanderpool
Joe G.N. Garcia
Jian Wang
Stephen M. Black
Source :
JACC. Basic to translational science, vol 3, iss 6, JACC: Basic to Translational Science, JACC: Basic to Translational Science, Vol 3, Iss 6, Pp 744-762 (2018)
Publication Year :
2018
Publisher :
Elsevier BV, 2018.

Abstract

Visual Abstract<br />Highlights • G protein-coupled receptors and tyrosine kinase receptors signal through the phosphoinositide 3-kinase/Akt/mTOR pathway to induce cell proliferation, survival, and growth. mTOR is a kinase present in 2 functionally distinct complexes, mTORC1 and mTORC2. • Functional disruption of mTORC1 by knockout of Raptor (regulatory associated protein of mammalian target of rapamycin) in smooth muscle cells ameliorated the development of experimental PH. • Functional disruption of mTORC2 by knockout of Rictor (rapamycin insensitive companion of mammalian target of rapamycin) caused spontaneous PH by up-regulating platelet-derived growth factor receptors. • Use of mTOR inhibitors (e.g., rapamycin) to treat PH should be accompanied by inhibitors of platelet-derived growth factor receptors (e.g., imatinib).<br />Summary Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension. We identified a differential role of mammalian target of rapamycin (mTOR) complex 1 and complex 2, two functionally distinct mTOR complexes, in the development of pulmonary hypertension (PH). Inhibition of mTOR complex 1 attenuated the development of PH; however, inhibition of mTOR complex 2 caused spontaneous PH, potentially due to up-regulation of platelet-derived growth factor receptors in pulmonary arterial smooth muscle cells, and compromised the therapeutic effect of the mTOR inhibitors on PH. In addition, we describe a promising therapeutic strategy using combination treatment with the mTOR inhibitors and the platelet-derived growth factor receptor inhibitors on PH and right ventricular hypertrophy. The data from this study provide an important mechanism-based perspective for developing novel therapies for patients with pulmonary arterial hypertension and right heart failure.

Subjects

Subjects :
phosphatase and tensin homolog
lcsh:Diseases of the circulatory (Cardiovascular) system
Raptor, regulatory associated protein of mammalian target of rapamycin
PH
Rictor, rapamycin insensitive companion of mammalian target of rapamycin
mTORC1
right ventricle
Pharmacology
Cardiovascular
PI3K
mTORC2
platelet-derived growth factor
smooth muscle
PRECLINICAL RESEARCH
GPCR
0302 clinical medicine
pulmonary arterial hypertension
PASMC
Lung
PDGFR, platelet-derived growth factor receptor
WT
mTORC1, mammalian target of rapamycin complex 1
rapamycin insensitive companion of mammalian target of rapamycin
HPH, hypoxia-induced pulmonary hypertension
PAEC
3. Good health
pulmonary arterial endothelial cell
TKR
endothelial cell
Cardiology and Cardiovascular Medicine
PA
Clinical Sciences
phosphorylated AKT
03 medical and health sciences
Right ventricular hypertrophy
pulmonary artery
G protein-coupled receptor
GPCR, G protein-coupled receptor
pulmonary arterial smooth muscle cell
EC, endothelial cell
mammalian target of rapamycin complex 2
mammalian target of rapamycin complex 1
medicine.disease
pAKT, phosphorylated AKT
WT, wild-type
030104 developmental biology
lcsh:RC666-701
0301 basic medicine
PTEN
PVR
Cardiorespiratory Medicine and Haematology
030204 cardiovascular system & hematology
PDGF, platelet-derived growth factor
SM, smooth muscle
RVSP
hypoxia-induced pulmonary hypertension
RVSP, right ventricular systolic pressure
pulmonary hypertension
right ventricular hypertrophy
regulatory associated protein of mammalian target of rapamycin
SM
phosphoinositide 3-kinase
PDGF
PAEC, pulmonary arterial endothelial cell
Raptor
PA, pulmonary artery
Heart Disease
medicine.anatomical_structure
HPH
pulmonary vascular resistance
mTORC2, mammalian target of rapamycin complex 2
mTOR
PAH, pulmonary arterial hypertension
PI3K, phosphoinositide 3-kinase
PASMC, pulmonary arterial smooth muscle cell
PDGFR
Forkhead box O3a
pAKT
PH, pulmonary hypertension
PVR, pulmonary vascular resistance
Rictor
FOXO3a, Forkhead box O3a
Rare Diseases
Growth factor receptor
TKR, tyrosine kinase receptor
medicine
right ventricular systolic pressure
FOXO3a
PI3K/AKT/mTOR pathway
wild-type
EC
business.industry
RVH, right ventricular hypertrophy
PAH
platelet-derived growth factor receptor
Pulmonary hypertension
PTEN, phosphatase and tensin homolog
Vascular resistance
tyrosine kinase receptor
business
RVH

Details

ISSN :
2452302X
Volume :
3
Database :
OpenAIRE
Journal :
JACC: Basic to Translational Science
Accession number :
edsair.doi.dedup.....db1d147fc74d88a884f1e521e7ef3c53